Clinical trial
Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of…
NCT00216593 · Janssen Pharmaceutica N.V., Belgium, Industry · Completed
Key facts
| NCT number | NCT00216593 |
|---|---|
| Title | Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study |
| Official title | Treatment of Severe Alzheimer's Disease in a Residential Home, Nursing Home, or Geriatric Residential Setting: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Randomised, Doubleblind, Placebo-Controlled Study. |
| Lead sponsor | Janssen Pharmaceutica N.V., Belgium, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Dementia, Alzheimer Disease |
| Intervention type | Drug |
| Interventions | galantamine hydrobromide |
| Enrollment | 415 |
| Start date | Dec 1, 2003 |
| Primary completion | Sep 1, 2007 |
| Completion | Mar 1, 2008 |
| First posted | Sep 22, 2005 |
| Last update posted | Jun 21, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: